NL2027551A - 1immunogenic polypeptides and pharmaceutical compositions - Google Patents

1immunogenic polypeptides and pharmaceutical compositions

Info

Publication number
NL2027551A
NL2027551A NL2027551A NL2027551A NL2027551A NL 2027551 A NL2027551 A NL 2027551A NL 2027551 A NL2027551 A NL 2027551A NL 2027551 A NL2027551 A NL 2027551A NL 2027551 A NL2027551 A NL 2027551A
Authority
NL
Netherlands
Prior art keywords
polypeptides
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
NL2027551A
Other versions
NL2027551B1 (en
Inventor
J Cruz Luis
Kit Chung Chih
Eich Christina
G Da Silva Cândido
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Priority to NL2027551A priority Critical patent/NL2027551B1/en
Priority to PCT/NL2022/050072 priority patent/WO2022173302A1/en
Application granted granted Critical
Publication of NL2027551A publication Critical patent/NL2027551A/en
Publication of NL2027551B1 publication Critical patent/NL2027551B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NL2027551A 2021-02-12 2021-02-12 1immunogenic polypeptides and pharmaceutical compositions NL2027551B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NL2027551A NL2027551B1 (en) 2021-02-12 2021-02-12 1immunogenic polypeptides and pharmaceutical compositions
PCT/NL2022/050072 WO2022173302A1 (en) 2021-02-12 2022-02-11 Immunogenic polypeptides and pharmaceutical compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2027551A NL2027551B1 (en) 2021-02-12 2021-02-12 1immunogenic polypeptides and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NL2027551A true NL2027551A (en) 2022-09-12
NL2027551B1 NL2027551B1 (en) 2022-09-12

Family

ID=76159871

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2027551A NL2027551B1 (en) 2021-02-12 2021-02-12 1immunogenic polypeptides and pharmaceutical compositions

Country Status (2)

Country Link
NL (1) NL2027551B1 (en)
WO (1) WO2022173302A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111892648A (en) * 2020-06-08 2020-11-06 中国科学院上海药物研究所 Novel coronavirus polypeptide vaccine coupled with TLR7 agonist and application thereof
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
CN111892648A (en) * 2020-06-08 2020-11-06 中国科学院上海药物研究所 Novel coronavirus polypeptide vaccine coupled with TLR7 agonist and application thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Peptide Backbone Modifications", CHEMISTRY AND BIOCHEMISTRY OF AMINO ACIDS PEPTIDES AND PROTEINS
AHMED SYED FARAZ ET AL: "Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies", VIRUSES, vol. 12, no. 3, 25 February 2020 (2020-02-25), CH, pages 1 - 15, XP055823903, ISSN: 1999-4915, DOI: 10.3390/v12030254 *
FLORINDO HELENA F ET AL: "Immune-mediated approaches against COVID-19", NATURE NANOTECHNOLOGY, NATURE PUB. GROUP, INC, LONDON, vol. 15, no. 8, 13 July 2020 (2020-07-13), pages 630 - 645, XP037212566, ISSN: 1748-3387, [retrieved on 20200713], DOI: 10.1038/S41565-020-0732-3 *
KIYOTANI KAZUMA ET AL: "Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2", JOURNAL OF HUMAN GENETICS, SPRINGER SINGAPORE, SINGAPORE, vol. 65, no. 7, 6 May 2020 (2020-05-06), pages 569 - 575, XP037153205, ISSN: 1434-5161, [retrieved on 20200506], DOI: 10.1038/S10038-020-0771-5 *
KUMAR VIPUL ET AL: "Reverse vaccinology approach towards the in-silico multiepitope vaccine development against SARS-CoV-2", F1000RESEARCH, vol. 10, 23 January 2021 (2021-01-23), pages 44, XP055857117, Retrieved from the Internet <URL:https://f1000researchdata.s3.amazonaws.com/manuscripts/39433/ea715dd5-43d8-48e7-8659-53f61986d324_36371_-_manoj_jena.pdf?doi=10.12688/f1000research.36371.1&numberOfBrowsableCollections=29&numberOfBrowsableInstitutionalCollections=4&numberOfBrowsableGateways=29> DOI: 10.12688/f1000research.36371.1 *
KWARTENG ALEXANDER ET AL: "Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques", BIOMEDICINE & PHARMACOTHERAPY, ELSEVIER, FR, vol. 132, 20 October 2020 (2020-10-20), XP086354746, ISSN: 0753-3322, [retrieved on 20201020], DOI: 10.1016/J.BIOPHA.2020.110914 *
LIN LI ET AL: "Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2", VIRUS RESEARCH, AMSTERDAM, NL, vol. 288, 1 July 2020 (2020-07-01), XP086262746, ISSN: 0168-1702, [retrieved on 20200701], DOI: 10.1016/J.VIRUSRES.2020.198082 *
SIROHI PREETI RANA ET AL: "Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein", JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 27 November 2020 (2020-11-27), US, pages 1 - 12, XP055857110, ISSN: 0739-1102, DOI: 10.1080/07391102.2020.1846626 *
SMITH CHRISTOF C. ET AL: "Landscape and Selection of Vaccine Epitopes in SARS-CoV-2", BIORXIV, 4 June 2020 (2020-06-04), pages 1 - 27, XP055845161, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.06.04.135004v1.full.pdf> [retrieved on 20210928], DOI: 10.1101/2020.06.04.135004 *
TOHIDINIA MARYAM ET AL: "Identification B and T-Cell epitopes and functional exposed amino acids of S protein as a potential vaccine candidate against SARS-CoV-2/COVID-19", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY, US, vol. 148, 21 August 2020 (2020-08-21), XP086352621, ISSN: 0882-4010, [retrieved on 20200821], DOI: 10.1016/J.MICPATH.2020.104459 *

Also Published As

Publication number Publication date
WO2022173302A1 (en) 2022-08-18
NL2027551B1 (en) 2022-09-12

Similar Documents

Publication Publication Date Title
GB202019241D0 (en) Pharmaceutical composition
GB2595109B (en) Pharmaceutical delivery compositions and uses thereof
EP4149470A4 (en) Pharmaceutical formulations and uses thereof
EP4183391A4 (en) Pharmaceutical composition and use thereof
IL287628A (en) Injectable pharmaceutical compositions and uses thereof
IL304290A (en) Pharmaceutical composition
EP4180040A4 (en) Pharmaceutical composition and application thereof
NL2027551A (en) 1immunogenic polypeptides and pharmaceutical compositions
FI4153133T3 (en) Injectable pharmaceutical compositions and uses thereof
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
GB202217964D0 (en) Pharmaceutical and cosmetic compositions comprising secretomes
EP4100020A4 (en) Aspacytarabine pharmaceutical compositions and uses thereof
GB202208464D0 (en) Pharmaceutical composition
GB202109271D0 (en) Pharmaceutical composition
GB202108387D0 (en) Pharmaceutical composition
GB202107518D0 (en) Pharmaceutical composition
GB202105858D0 (en) Pharmaceutical composition
GB202105462D0 (en) Pharmaceutical composition
GB202105047D0 (en) Pharmaceutical composition
GB202105049D0 (en) Pharmaceutical composition
GB202104224D0 (en) Pharmaceutical composition
GB202102095D0 (en) Pharmaceutical composition
GB202102100D0 (en) Pharmaceutical composition
GB202101640D0 (en) Pharmaceutical composition
GB202101638D0 (en) Pharmaceutical composition